Take­da part­ners with Noile-Im­mune on next-gen CAR-T pipeline for sol­id tu­mors

Take­da is stak­ing out a new part­ner­ship it hopes will put it out front as new CAR-T drugs an­gle for a big break in­to sol­id tu­mors.

The phar­ma com­pa­ny is part­ner­ing with the start­up Noile-Im­mune Biotech, which is pur­su­ing what it says is a next-gen ap­proach to CAR-T.

No­var­tis just scored the pi­o­neer­ing reg­u­la­to­ry win in the field, fol­lowed close­ly by Kite Phar­ma. But these first ther­a­pies, which use reengi­neered T cells ex­tract­ed from pa­tients to at­tack hema­to­log­i­cal ma­lig­nan­cies, have been lim­it­ed in scope. Take­da and Tokyo-based Noile-Im­mune hope to use new tech de­vel­oped with re­searchers at Ya­m­aguchi Uni­ver­si­ty to over­come those lim­i­ta­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER